Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
Background Anti-PD-(L)1 agents are standard of care treatments in various cancers but predictive factors for therapy selection are limited. We hypothesised that markers of systemic inflammation would predict adverse outcomes in multiple cancers treated with anti-PD-(L)1 agents.Material and methods D...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-07-01
|
| Series: | ESMO Open |
| Online Access: | https://esmoopen.bmj.com/content/4/4/e000531.full |